Navigation Links
Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
Date:8/29/2007

ts underwent genomic testing for variations in the coding regions of genes known to influence memory and cognition, including the apolipoprotein E gene (APOE), a known genetic risk factor for Alzheimer's disease (AD) that occurs in 15-20% of the general population. On days 0, 30, 60, 90 and 104, subjects were evaluated through a battery of neuropsychometric tests that measure various aspects of memory and cognition.

Ketasyn showed significant efficacy in tests of memory. On average, subjects taking Ketasyn performed significantly better on the 'First-Last Name Association' test (FLN) than subjects taking placebo (p=0.042). "On average, seniors taking Ketasyn remembered more names than those taking placebo," said Dr. Costantini.

In another memory test called Name-Face Recognition (NFA), which associates a person's name and face, Ketasyn subjects under age 59 improved significantly more than placebo subjects at Day 90 (p=0.0217). The efficacy in the NFA test observed with Ketasyn in subjects under age 59 captures a large portion of the AAMI population.

Consistent with the findings of Accera's Phase IIa and IIb AD studies, subjects who did not have the APOE4 genotype (E4(-)) responded particularly well to treatment: E4(-) subjects showed a further significant treatment effect of Ketasyn in FLN at Day 90 (p=0.012). In contrast, and also consistent with the AD trial results, APOE4(+) subjects showed no difference between Ketasyn and placebo for FLN scores at Day 90 (p=0.4639).

The safety profile of Ketasyn was excellent, as shown in the previous AD trials with Ketasyn. The incidence of adverse events was low and similar between Ketasyn and placebo groups.

Accera recently completed a Phase IIb clinical trial in AD patients that confirmed Ketasyn's safety and efficacy as measured by improvement in ADAS-Cog scores, the gold standard measure for efficacy in cognition and short-term memory. Accera plans to initiate a pivotal, Phase III multi-cent
'/>"/>

SOURCE Accera, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
2. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
3. Mayo Clinic News Release: Mayo Clinic-led Study Improves Breast Cancer Risk Prediction in Women with Atypia
4. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
5. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and Maintenance vs. Placebo
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
10. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
11. First-of-Its-Kind Study Shows Botox (Botulinum Toxin Type A) Significantly Improves Idiopathic Detrusor Overactivity (IDO) in Patients With Symptoms of Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... on the development and commercialization of novel bile acid ... pricing of an underwritten public offering of 1,730,000 shares ... of $33.01 per share.  In addition, Intercept has granted ... an additional 259,500 shares of common stock. ...
(Date:6/18/2013)... 18, 2013  Actavis, Inc. (NYSE: ACT ) ... the U.S. Securities and Exchange Commission (SEC) a registration statement ... Warner Chilcott plc (NASDAQ: WCRX ), ... Warner Chilcott (the "Form S-4"). As previously ... have entered into a definitive agreement pursuant to which ...
(Date:6/18/2013)...  Recent regulatory and budget challenges have made it ... large pharmaceutical companies to effectively educate doctors and other ... their new products. With the pressure to reduce budgets ... these "Med Ed" groups find practical, economical ... the changes that are transforming the Medical Education area ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... May 5, 2011 Novartis Pharmaceuticals Corporation ("Novartis") announced ... approved Afinitor® (everolimus) tablets for the treatment of progressive ... unresectable, locally advanced or metastatic disease(4). This marks the ... in the US in nearly 30 years(5). ...
... FRANCISCO, May 5, 2011 Cardiac Network, Inc. (Other OTC: ... a 1-for-750 reverse stock split (the "Reverse Stock Split"). The ... business and trading on May 6, 2011 (the "Effective Date"). ... changed from "CNWI" to "CNWID" for approximately 20 business days, ...
Cached Medicine Technology:Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 2Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 3Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 4Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 5Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 6Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 7Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 8Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 9Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET 10Cardiac Network Announces Reverse Stock Split 2
(Date:6/18/2013)... Exposed Skin Care has finally been released after much anticipation ... finally achieve the clear, beautiful skin they have always dreamed ... system combines the power of science and nature to both ... , After a quick review of Exposed Skin ... most effective available on the market to cure acne both ...
(Date:6/18/2013)... Recent studies linking bullying and depression, coupled with ... people, led the Centers for Disease Control and ... focus on these issues. This panel synthesized the ... involvement in bullying and suicide-related behaviors. Three themes ... public health problem, with widespread and often harmful ...
(Date:6/18/2013)... An apple a day might really keep ... with breast cancer, she chose a different method for ... Myself Cancer, I Can Take It Away!: Alternatives Brought ... explains how changing her physical, mental and emotional diet ... made to feel fearful when diagnosed with a disease ...
(Date:6/18/2013)... Cheap Concert Tickets has released additional inventories ... gets underway in July. Soccer fans can add code ... , The popularity and hype of soccer has ... the hype of the game triggered the sports-minded citizens of ... the veins of fans from the Caribbean. The adrenalin ...
(Date:6/18/2013)... As obesity rates sky rocket in the United ... during childbirth comes as no shock. Forceps are surgical equipment ... she is unable to do so herself and although they ... rates of complication for both the mother and the baby. ... and child, forceps births add to the pressure of healthcare ...
Breaking Medicine News(10 mins):Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Bullying and suicide among youth is a public health problem 2Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 3Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2
... Mayo Clinic researchers have discovered that a chemical known ... for the effectiveness of tamoxifen in treating breast cancer, ... unexpected way. , Their study, being presented at the ... (CTRC-AACR) 31st annual San Antonio Breast Cancer Symposium, finds ...
... their lower back pain are better off than those who ... a University of Alberta study. , The study, done in ... cent improvement in pain and function levels for people with ... of resistance training using dumbbells, barbells and other load-bearing exercise ...
... Liverpool Associates in Tropical Health (LATH), a consulting arm ... a 10 million contract to manage a programme of ... initiative in Malawi. , Led by the National ... 5 year programme supported by the Wellcome Trust, the ...
... large proteomics study on the brains of newborn mice ... obstetric or pediatric medicine can have profound and long-term ... study, appearing in the December issue of Molecular ... the developing nervous system and reinforces the use of ...
... TCM Inc. of West Chester, PA ... named PCM Solutions, LLC, with Nalco Company ... the process industries, such as chemical and petrochemical manufacturing, ... paper manufacturing, food and beverage production, and various other ...
... Enhances First Global Medical Donations Map , ... The Partnership for Quality Medical Donations (PQMD) Mapping Tool, ... to information about the medical product donations being made ... to the world,s most vulnerable populations. Both the ...
Cached Medicine News:Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:LATH wins contract to boost health research capacity in Malawi 2Health News:The profound effects of numbing agents 2Health News:Haas TCM Inc. Forms PCM Solutions, LLC, a Joint Venture With Nalco Company, to Provide Chemical Management Services (CMS) to the Process Industries 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 2Health News:Global Mapping Tool Demonstrates Medical Donation Impact 3
Hollow Copper Tube with Suction Port 16.5....
Aluminum Stylette 16 with Adjustable Stop....
Ultra-Slip™ endotracheal tube guide for single-patient use only., ,Caution: Not MRI Compatible....
Aluminum Stylette 16....
Medicine Products: